Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc(TMO)股票分析

$622.180

-8.399 (-1.35%)收盘时

Loading chart…
High
630.000
Open
626.580
VWAP
623.21
Vol
1.02M
Mkt Cap
210.24B
Low
617.450
Amount
633.57M
EV/EBITDA, TTM
21.95

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.

AI analysis of Thermo Fisher Scientific Inc (TMO)

buy

Thermo Fisher Scientific Inc is a good buy right now, trading at $622.18 with a forward P/E of 25.25, indicating potential for growth relative to its earnings. The stock has shown a strong year-over-year performance with a 27.62% increase and is favored by hedge funds, as highlighted by Goldman Sachs' report. However, a key risk is the current RSI of 57.01, suggesting it is nearing overbought territory.

Analyst Ratings (15)

+5.90% upside
Buy
14 Buy
1 Hold
0 Sell
Current: 622.18
最低
580.00
平均
658.89
最高
750.00

Piper Sandler

2026-07-27

目标价

$600

Neutral

Morgan Stanley

2026-07-24

目标价

$650

Overweight

RBC Capital

2026-07-24

目标价

$580

Sector Perform

Barclays

2026-07-24

目标价

$650

Overweight

BofA

2026-07-23

目标价

$650

Buy

估值指标

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO) is 25.25, compared to its 5-year average forward P/E of 23.95.

Forward P/E

Fair
5Y Average P/E
23.95
Current P/E
25.25
高估
26.88
低估
21.02

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
20.77
Current EV/EBITDA
21.95
高估
22.72
低估
18.82

Forward P/S

Fair
5Y Average P/S
4.75
Current P/S
4.63
高估
5.43
低估
4.06

Alphio AI Price Scenarios for TMO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TMO

$539.08

情景价格

B

Base

Base · 50%TMO

$476.92

情景价格

B

Bear

Bear · 25%TMO

$435.11

情景价格

Whales holding TMO

A

Armistice Capital LLC

+ HoldingTMO

+13.92%

3M Return

S

Sculptor Capital Management, Inc.

+ HoldingTMO

+9.80%

3M Return

O

Old National Bancorp

+ HoldingTMO

+9.27%

3M Return

B

Bellevue Asset Management AG

+ HoldingTMO

+9.20%

3M Return

E

EdgePoint Investment Group Inc.

+ HoldingTMO

+9.03%

3M Return

C

Chilton Investment Company, Inc.

+ HoldingTMO

+8.90%

3M Return

事件时间线

2026-08-27 (ET)

09:00:00

Thermo Fisher Launches New EMPAD G2 Detector

2026-08-12 (ET)

08:30:00

Thermo Fisher Completes Sale of Microbiology Business for Approximately $1.075B

2026-07-23 (ET)

14:30:00

Raises FY26 Revenue to $47.4B-$48.1B

10:00:00

Notable Gainers This Morning Include United Rentals and Others

09:30:00

Dow, S&P 500, and Nasdaq Futures Decline

资讯

TMO FAQ — answered by Alphio AI

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Thermo Fisher Scientific Inc is a good buy right now, trading at $622.18 with a forward P/E of 25.25, indicating potential for growth relative to its earnings. The stock has shown a strong year-over-year performance with a 27.62% increase and is favored by hedge funds, as highlighted by Goldman Sachs' report. However, a key risk is the current RSI of 57.01, suggesting it is nearing overbought territory.

15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始